Advertisement
Screener

KALARIS THERAPEUTICS, INC. (KLRS) Income Tax Expense

2.8 / 5 stars · 68/120 Roast Me

KALARIS THERAPEUTICS, INC. Income Tax Expense

KALARIS THERAPEUTICS, INC. (KLRS) reported Income Tax Expense of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.

Financial Statements › Expense Statement › Income Tax

us-gaap:IncomeTaxExpenseBenefit · last filed 2026-03-17

  • KALARIS THERAPEUTICS, INC. income tax expense (benefit) for the quarter ending 2024-09-30 was $0.00.
  • KALARIS THERAPEUTICS, INC. income tax expense (benefit) for the quarter ending 2024-06-30 was $0.00.
  • KALARIS THERAPEUTICS, INC. income tax expense (benefit) for the quarter ending 2024-03-31 was $0.00.
  • KALARIS THERAPEUTICS, INC. income tax expense (benefit) for the quarter ending 2023-12-31 was -$126.00K.
  • KALARIS THERAPEUTICS, INC. income tax expense (benefit) for fiscal 2025 was $0.00.
  • KALARIS THERAPEUTICS, INC. income tax expense (benefit) for fiscal 2024 was $0.00.
  • KALARIS THERAPEUTICS, INC. income tax expense (benefit) for fiscal 2023 was -$126.00K.
  • KALARIS THERAPEUTICS, INC. income tax expense (benefit) for fiscal 2022 was -$265.00K, a 126.32% decline from fiscal 2021.
Period endIncome Tax Expense (Benefit) 3 monthIncome Tax Expense (Benefit) 6 monthIncome Tax Expense (Benefit) 9 monthIncome Tax Expense (Benefit) 12 month
2025-12-31$0.00
10-K · filed 2026-03-17
2024-12-31$0.00
10-K · filed 2026-03-17
2024-09-30$0.00
10-Q · filed 2024-11-12
$0.00
derived: sum of 2 quarters · filed 2024-11-12
$0.00
derived: sum of 3 quarters · filed 2024-11-12
-$126.00K
derived: sum of 4 quarters · filed 2025-03-07
2024-06-30$0.00
10-Q · filed 2024-08-09
$0.00
derived: sum of 2 quarters · filed 2024-08-09
-$126.00K
derived: sum of 3 quarters · filed 2025-03-07
-$126.00K
derived: sum of 4 quarters · filed 2025-03-07
2024-03-31$0.00
10-Q · filed 2024-05-13
-$126.00K
derived: sum of 2 quarters · filed 2025-03-07
-$126.00K
derived: sum of 3 quarters · filed 2025-03-07
-$126.00K
derived: sum of 4 quarters · filed 2025-03-07
2023-12-31-$126.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07
-$126.00K
derived: sum of 2 quarters · filed 2025-03-07
-$126.00K
derived: sum of 3 quarters · filed 2025-03-07
-$126.00K
10-K · filed 2025-03-07
2023-09-30$0.00
10-Q · filed 2024-11-12
$0.00
derived: sum of 2 quarters · filed 2024-11-12
$0.00
10-Q · filed 2023-11-02
-$415.00K
derived: sum of 4 quarters · filed 2024-11-12
2023-06-30$0.00
10-Q · filed 2024-08-09
$0.00
10-Q · filed 2023-08-03
-$415.00K
derived: sum of 3 quarters · filed 2024-08-09
-$415.00K
derived: sum of 4 quarters · filed 2024-08-09
2023-03-31$0.00
10-Q · filed 2024-05-13
-$415.00K
derived: sum of 2 quarters · filed 2024-05-13
-$415.00K
derived: sum of 3 quarters · filed 2024-05-13
-$265.00K
derived: sum of 4 quarters · filed 2024-05-13
2022-12-31-$415.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15
-$415.00K
derived: sum of 2 quarters · filed 2024-03-15
-$265.00K
derived: sum of 3 quarters · filed 2024-03-15
-$265.00K
10-K · filed 2024-03-15
2022-09-30$0.00
10-Q · filed 2023-11-02
$150.00K
derived: sum of 2 quarters · filed 2023-11-02
$150.00K
10-Q · filed 2023-11-02
2022-06-30$150.00K
10-Q · filed 2023-08-03
$150.00K
10-Q · filed 2023-08-03
2022-03-31$0.00
10-Q · filed 2022-05-05
2021-12-31$1.01M
10-K · filed 2023-02-15
2021-03-31$0.00
10-Q · filed 2022-05-05

Similar stocks

Stock NameCountryMarket CapPE Ratio
CHAMPIONS ONCOLOGY, INC. (CSBR)United States$0.070B-68.02
BioStem Technologies, Inc. (BSEM)United States$0.069B
Vaxart, Inc. (VXRT)United States$0.080B3.84
Eloxx Pharmaceuticals, Inc. (ELOX)United States$0.065B
MiNK Therapeutics, Inc. (INKT)United States$0.063B-5.37
Atara Biotherapeutics, Inc. (ATRA)United States$0.086B-6.48
Pelthos Therapeutics Inc. (PTHS)United States$0.086B-1.20
EXOZYMES INC. (EXOZ)United States$0.058B
BioAtla, Inc. (BCAB)United States$0.058B-0.21
COGNITION THERAPEUTICS INC (CGTX)United States$0.090B-6.52